One Year Finasteride Therapy in Men with a Serum PSA Greater Than 4 ng/mL Who Had Undergone Repeat Biopsy

The study involved 40 men with a mean age of 66.2 years, all having a baseline serum PSA level greater than 4 ng/mL and benign prostatic hyperplasia. They were treated with 5 mg of finasteride daily for one year. Results showed significant reductions in PSA levels (46.5%) and prostate volume (24.3%), along with improvements in the International Prostate Symptom Score (IPSS) and maximal flow rate (MFR). Prostate cancer (CaP) was detected in 3 cases (7.5%), and high-grade prostatic intraepithelial neoplasia (HIPIN) in 2 cases (5%). The study concluded that the changes in PSA and prostate volume after one year of finasteride therapy could be useful in diagnosing prostate cancer in patients with elevated PSA levels and prior negative biopsies.